Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Molecular response of Acute Myeloid Leukemia to induction with CPX-351 and its impact on prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFriederike KratzschEBElżbieta BrzuszkiewiczHCHannah Casper

Discussion

Loading...

Member takes

Overview

Observational analysis shows molecular profiling improves prognosis in acute myeloid leukemia patients treated with CPX-351, indicating its clinical significance.

Key Points

  • Molecular profiling reveals significant variations in genetic mutations associated with patient outcomes, refining prognosis in acute myeloid leukemia.
  • A total of 73 patients were treated with CPX-351 induction, contributing to insights on genetic and molecular responses after therapy.
  • Induction therapy led to a 24% rate of complete and very good molecular remissions, compared to a 78% conventional remission rate, indicating the need for molecular analysis.
  • Genetic mutations like RUNX1 and TP53 play pivotal roles in determining remission and survival outcomes for patients with acute myeloid leukemia.

Cite This Study

Kratzsch et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c8https://doi.org/10.1182/blood-2025-7048
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.2025
  2. 2Outcomes with liposomal daunorubicin/cytarabine – a single-center experience2025
  3. 3Real‐world analysis of CPX ‐351 in AML ‐ MR : A multicentre study from the MARROW consortium2025 · 1 citations
  4. 4Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.2025
  5. 5CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.2025